These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 36933851)

  • 21. Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination.
    Wang F; Huang B; Lv H; Feng L; Ren W; Wang X; Tang L; Liu Q; Wu D; Zheng H; An Z; Deng Y; Zhao L; Ye F; Wang W; Zhang H; Chang S; Liao Y; Chen F; Rodewald LE; Gao GF; Yin Z; Tan W
    Front Immunol; 2022; 13():967051. PubMed ID: 36159863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A real-world study of BBIBP-CorV vaccine effectiveness in a Sri Lanka rural province.
    Wijekoon L; Wickramasinghe N; Rathnasekara T; Somathilake T; Sarathchandra C; Senanayake H; Weerawansa P; Ganegama R; Zhang Y; Yang Y; Ma R; Zhang Y; Xie D; Li Z; Liu X; Qin S; Siribaddana S
    Heliyon; 2024 Sep; 10(18):e37662. PubMed ID: 39323840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
    Joudi M; Moradi Binabaj M; Porouhan P; PeyroShabany B; Tabasi M; Fazilat-Panah D; Khajeh M; Mehrabian A; Dehghani M; Welsh JS; Keykhosravi B; Akbari Yazdi A; Ariamanesh M; Ghasemi A; Ferns G; Javadinia SA
    Front Endocrinol (Lausanne); 2022; 13():798975. PubMed ID: 35299966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection.
    Hueda-Zavaleta M; Gómez de la Torre JC; Cáceres-Del Aguila JA; Muro-Rojo C; De La Cruz-Escurra N; Arenas Siles D; Minchón-Vizconde D; Copaja-Corzo C; Bardales-Silva F; Benites-Zapata VA; Rodriguez-Morales AJ
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary SARS-CoV-2 Infections, Re-infections and Vaccine Effectiveness during the Omicron Transmission Period in Healthcare Workers of Trieste and Gorizia (Northeast Italy), 1 December 2021-31 May 2022.
    Cegolon L; Negro C; Mastrangelo G; Filon FL;
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560692
    [No Abstract]   [Full Text] [Related]  

  • 26. Altered T-cell receptor β repertoire in adults with SARS CoV-2 inactivated vaccine of BBIBP-CorV.
    Quan Z; Qi A; Ma S; Li Y; Chen H; Yu X; Dong T; Li K; Qiu Y
    Mol Immunol; 2023 Oct; 162():54-63. PubMed ID: 37647774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Humoral Response after a Fourth Dose with mRNA-1273 in Healthcare Workers with and without a History of SARS-CoV-2 Infection and Previously Vaccinated with Two Doses of BBIBP-CorV Plus BNT162b2 Vaccine.
    Gómez de la Torre JC; Hueda-Zavaleta M; Cáceres-DelAguila JA; Muro-Rojo C; Cruz-Escurra N; Benítes-Zapata VA
    Vaccines (Basel); 2023 Apr; 11(5):. PubMed ID: 37242998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study.
    Gómez de la Torre JC; Cáceres-DelAguila JA; Muro-Rojo C; De La Cruz-Escurra N; Copaja-Corzo C; Hueda-Zavaleta M; Arenas Siles D; Benites-Zapata VA
    Trop Med Infect Dis; 2022 Apr; 7(5):. PubMed ID: 35622693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study.
    Muhsen K; Maimon N; Mizrahi A; Bodenheimer O; Cohen D; Maimon M; Grotto I; Dagan R
    Clin Infect Dis; 2022 Aug; 75(1):e755-e763. PubMed ID: 34698808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal.
    Rayamajhi S; Rafi MA; Tripathi N; Dongol AS; Pandey M; Rayamajhi S; Bhandari S; Shrestha P; Hasan MT; Hossain MG
    PLoS One; 2022; 17(8):e0272729. PubMed ID: 35947626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease.
    Wang C; Chen LY; Lu QB; Cui F
    Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults.
    Wang Q; Ning J; Chen Y; Li B; Shi L; He T; Zhang F; Chen X; Zhai A; Wu C
    Front Microbiol; 2022; 13():1008420. PubMed ID: 36406456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study.
    Musa S; Merdrignac L; Skocibusic S; Nedic R; Cilovic-Lagarija S; Kissling E
    Vaccine; 2024 May; 42(15):3467-3473. PubMed ID: 38644077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine.
    Chansaenroj J; Suntronwong N; Kanokudom S; Assawakosri S; Yorsaeng R; Vichaiwattana P; Klinfueng S; Wongsrisang L; Srimuan D; Thatsanatorn T; Thongmee T; Auphimai C; Nilyanimit P; Wanlapakorn N; Sudhinaraset N; Poovorawan Y
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine.
    Ferenci T; Sarkadi B
    BMC Infect Dis; 2022 Jan; 22(1):87. PubMed ID: 35073866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the humoral response induced by BBIBP-CorV vaccine by determining neutralizing antibodies in peruvian healthcare personnel.
    Soto A; Charca-Rodríguez FM; Pareja-Medina M; Fernandez-Navarro M; Altamirano-Cáceres K; Sierra Chávez E; Raraz-Vidal J; Cabezudo-Pillpe N; Velarde-Rodríguez M; Alcántara-Díaz A
    Rev Peru Med Exp Salud Publica; 2021; 38(4):493-500. PubMed ID: 35385001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm.
    Anvari E; Ghamar Talepoor A; Eshkevar Vakili M; Karimi N; Ataollahi M; Najafi G; Kabelitz D; Ahmadi I; Kalantar K
    Iran J Immunol; 2022 Sep; 19(3):321-329. PubMed ID: 36190385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing.
    Tong R; Luo L; Zhao Y; Sun M; Li R; Zhong J; Chen Y; Hu L; Li Z; Shi J; Lyu Y; Hu L; Guo X; Liu Q; Shuang T; Zhang C; Yuan A; Sun L; Zhang Z; Qian K; Chen L; Lin W; Chen AF; Wang F; Pu J
    Emerg Microbes Infect; 2023 Dec; 12(1):e2187245. PubMed ID: 36987861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study.
    Al-Rifai RH; Alhosani F; Abuyadek R; Atef S; Donnelly JG; Leinberger-Jabari A; Ahmed LA; Altrabulsi B; Alatoom A; Alsuwaidi AR; AbdelWareth L
    Front Med (Lausanne); 2022; 9():1092646. PubMed ID: 36703898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai.
    Bao Y; He L; Miao B; Zhong Z; Lu G; Bai Y; Liang Q; Ling Y; Ji P; Su B; Zhao GP; Wu H; Zhang W; Wang Y; Chen Y; Xu J
    Vaccine; 2023 May; 41(20):3258-3265. PubMed ID: 37085449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.